marketing-medtech

**Country:** Austria (Vienna; offices in Budapest and London)
**Founder:** Tamás Petrovics — Co-founder & CEO
**Background:** other | verified: False — Business / management consulting. Before co-founding XUND in 2018, Tamás Petrovics worked as a management consultant at McKinsey & Company (most recently as a Junior Engagement Manager), with 5+ years of international consulting experience. He holds an MSc in International Management (CEMS, 2013–2015). He co-founded XUND with longtime friends Lukas Seper and Dr. Zoltán Tarabó.
**Stage / fundraise:** Scale-up (NOT early-stage). Founded 2018; 40+ employees across Vienna, Budapest and London. Pre-Series A stage as of March 2025, with an established, MDR-certified product already in market. / €6M pre-Series A closed March 2025 (Lead Ventures, J&T Ventures; existing MassMutual Ventures, tba network, LANA Ventures). Seed previously extended to €8M. Actively scaling DACH + UK.
**Regulatory trigger:** XUND's products are CE-marked as Class IIa medical devices under EU MDR (Symptom Check and Illness Check; the Medical API itself is the certified device). QMS adheres to ISO 13485. MDR is core to their business — funding press explicitly cites "increasing demand for solutions with MDR certification." Note: certification is already ACHIEVED, so the trigger is maintaining/extending the MDR technical file and IEC 62304 traceability as they expand the product and add the RAVE LLM, not a first-time CE milestone ahead.
**Email:** tamas.petrovics@xund.ai (confidence low) — No personal email is published. The only confirmed/published addresses are the general hello@xund.ai (XUND contact page) and press@xund.ai (press page). first.last@xund.ai is a plausible corporate pattern but is UNCONFIRMED for this domain, hence low confidence. Safer outreach route: hello@xund.ai (published) or LinkedIn DM. Imprint entity: XUND Solutions GmbH, Dorotheergasse 10/12a, 1010 Wien.
**LinkedIn:** https://www.linkedin.com/in/tamas-petrovics/ **Website:** https://xund.ai
**Score:** 6 -> Tier C
**Hook:** Reference their March 2025 €6M pre-Series A and the explicit plan to "advance MDR-certified solutions" and integrate the RAVE LLM while expanding DACH + UK. Angle for an ex-McKinsey, business-led founder: adding an LLM to a Class IIa MDR product multiplies the compliance-evidence and traceability workload right as the team is stretched thin by geographic expansion. OmDev can add senior dev capacity + a dedicated CTO at a fixed monthly price (~3x cheaper than hiring that team in-house), with a pipeline that produces a SOUP register signed at every build and requirements-to-code-to-test traceability feeding the IEC 62304/MDR technical file — letting XUND ship RAVE and new markets faster without diluting runway on headcount. (Caveat: they have 40+ staff and likely existing RA/QA, so position as overflow/acceleration, not a replacement team.)

---

## Founder & background
Tamás Petrovics is Co-founder & CEO of XUND, co-founded in 2018 with Lukas Seper and Dr. Zoltán Tarabó (friends of 25+ years). His background is management consulting — a Consultant at McKinsey & Company — plus an MSc in International Management (CEMS). Business/strategy-led, non-technical, non-clinical founder; no finance/insurance background is confirmed, so this scores as "other" rather than the priority finance/insurance signal. Sources: [Crunchbase](https://www.crunchbase.com/person/tam%C3%A1s-petrovics), [EU-Startups](https://www.eu-startups.com/2025/03/healthtech-startup-xund-secures-e6-million-to-strengthen-european-leadership-in-ai-powered-healthcare/).

## Funding & momentum
Closed a €6M pre-Series A in March 2025, led by Lead Ventures with J&T Ventures, plus existing backers MassMutual Ventures, tba network and LANA Ventures; an earlier seed was extended to €8M. Capital is earmarked for DACH + UK expansion, advancing MDR-certified solutions, and integrating the RAVE LLM. Actively scaling — a Series A is the plausible next raise. Sources: [EU-Startups](https://www.eu-startups.com/2025/03/healthtech-startup-xund-secures-e6-million-to-strengthen-european-leadership-in-ai-powered-healthcare/), [Vestbee](https://www.vestbee.com/insights/articles/scale-up-xund-secures-6-m), [XUND blog](https://xund.ai/blog/xund-secures-pre-series-6-million-euros-strengthen-european-leadership-ai-powered-healthcare).

## Product & regulatory
Pure-play SaMD: a certified Medical API (the API itself is the regulated device) powering Symptom Check and Illness Check, with RAVE as their LLM layer. Both Symptom Check and Illness Check are CE-marked as **Class IIa medical devices under EU MDR**, with an ISO 13485 QMS. The IEC 62304/MDR compliance-evidence angle is directly relevant — but certification is already achieved, so the live need is maintaining/extending the technical file (especially for the new LLM) rather than a first CE milestone. Sources: [XUND Medical API](https://xund.ai/product/medical-api), [Illness Check](https://xund.ai/products/illness-check).

## Pain & buying signals
Adding an LLM (RAVE) to a Class IIa MDR product sharply increases AI-under-MDR / IEC 62304 evidence, SOUP management and change-control work, exactly as the team is stretched across two new markets (DACH + UK). Counter-signal: 40+ staff and an in-market certified product imply an existing internal dev and RA/QA team and a CTO-equivalent — so the classic "thin team / no CTO" OmDev fit is weak. Sources: [Vestbee](https://www.vestbee.com/insights/articles/scale-up-xund-secures-6-m), [EU-Startups](https://www.eu-startups.com/2025/03/healthtech-startup-xund-secures-e6-million-to-strengthen-european-leadership-in-ai-powered-healthcare/).

**Why OmDev fits (with caveats):** OmDev can supply senior dev capacity + a dedicated CTO at a fixed monthly price (~3x cheaper than building in-house), with a pipeline that signs a SOUP register at every build and produces requirements-to-code-to-test traceability feeding the IEC 62304/MDR technical file (refs: CadSmile, SpeechLink) — useful to accelerate RAVE and new-market builds without burning runway on hiring. Position as **overflow/acceleration + compliance-evidence engine**, not a team replacement. Overall this is a weaker, later-stage prospect than the ICP (founded 2018, scaled team, already certified) → **Tier C**.

---
**Sources:** https://www.eu-startups.com/2025/03/healthtech-startup-xund-secures-e6-million-to-strengthen-european-leadership-in-ai-powered-healthcare/ · https://xund.ai/blog/xund-secures-pre-series-6-million-euros-strengthen-european-leadership-ai-powered-healthcare · https://www.vestbee.com/insights/articles/scale-up-xund-secures-6-m · https://www.crunchbase.com/person/tam%C3%A1s-petrovics · https://therecursive.com/healthtech-scale-up-xund-secures-e6m-in-pre-series-a-funding/ · https://xund.ai/product/medical-api · https://xund.ai/products/illness-check · https://xund.ai/contact · https://xund.ai/press · https://xund.ai/imprint · https://www.linkedin.com/in/tamas-petrovics/